Proteins NT-3 , Human
- Known as:
- Proteins NT-3 , Human
- Catalog number:
- C079
- Product Quantity:
- 10μg
- Category:
- -
- Supplier:
- Novoprotein
- Gene target:
- Proteins NT-3 Human
Related genes to: Proteins NT-3 , Human
- Gene:
- GCNT4 NIH gene
- Name:
- glucosaminyl (N-acetyl) transferase 4
- Previous symbol:
- LINC01336
- Synonyms:
- C2GNT3
- Chromosome:
- 5q13.3
- Locus Type:
- gene with protein product
- Date approved:
- 2006-02-06
- Date modifiied:
- 2018-10-18
- Gene:
- INTS3 NIH gene
- Name:
- integrator complex subunit 3
- Previous symbol:
- C1orf60
- Synonyms:
- FLJ21919, INT3, SOSS-A
- Chromosome:
- 1q21.3
- Locus Type:
- gene with protein product
- Date approved:
- 2005-05-13
- Date modifiied:
- 2014-11-19
- Gene:
- NOTCH4 NIH gene
- Name:
- notch receptor 4
- Previous symbol:
- INT3
- Synonyms:
- -
- Chromosome:
- 6p21.32
- Locus Type:
- gene with protein product
- Date approved:
- 1994-07-04
- Date modifiied:
- 2019-01-03
- Gene:
- NT3 NIH gene
- Name:
- 3'-nucleotidase
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- reserved
- Locus Type:
- unknown
- Date approved:
- 1989-02-23
- Date modifiied:
- 2013-03-27
- Gene:
- SLC25A6 NIH gene
- Name:
- solute carrier family 25 member 6
- Previous symbol:
- ANT3
- Synonyms:
- ANT3Y, MGC17525
- Chromosome:
- Xp22.32 and Yp11.3
- Locus Type:
- gene with protein product
- Date approved:
- 1990-08-03
- Date modifiied:
- 2016-02-18
Related products to: Proteins NT-3 , Human
Related articles to: Proteins NT-3 , Human
- Abnormal glycolysis is one of the hallmarks of cancer and plays a significant role in its progression. This study investigates the association between glycolysis genes and the progression of lung adenocarcinoma (LUAD). Utilizing various bioinformatics techniques, the research explores the heterogeneity of glycolysis genes in different LUAD cell types, identifies glycolysis-related prognostic signatures (GRPS). We obtained one training set for model construction from the Cancer Genome Atlas (TCGA) database, and also obtained four LUAD gene expression datasets as validation sets from the Gene Expression Omnibus (GEO) database. The single-cell RNA sequencing (scRNA seq) data also comes from the GEO database. Firstly, the "limma" R package was used to identify differentially expressed glycolysis related genes, and a machine learning computational framework composed of multiple combinations was used to preliminarily screen for glycolysis related prognostic markers (GRPS) in LUAD. Based on these GRPS, prognostic features were developed and validated through survival analysis, column chart development, and ROC curve analysis. The ssGSEA algorithm, ESTIMATE algorithm, and seven integrated computational algorithms from the TIMER 2.0 database were used to analyze the immune cell infiltration patterns of different risk groups. Analyze scRNA seq data to evaluate the distribution of GRPS and intercellular communication among various cell types, and further determine the core GRPS through the "hdWGCNA" and "ConstructNetwork" packages. In addition, we also evaluated the responsiveness of high and low-risk groups to 198 drugs using the "OncoPredict" software package. Result: We found that the glycolytic activity score of tumor tissue was significantly higher than that of normal tissue, and a total of 49 upregulated genes and 15 downregulated genes were selected from the total. Based on a machine learning computational framework, a total of 8 GRPS were screened, which constitute the prognostic features of LUAD patients. This feature demonstrates strong prognostic value, as confirmed by univariate and multivariate Cox regression analysis. Significant differences in tumor microenvironment (TME) immune infiltration were observed between high and low-risk groups. ScRNA seq revealed the distribution and expression of cell type specific GRPS, particularly in T cells, epithelial cells, and fibroblasts, while also revealing the strong cell-cell communication ability of the high GRPS group. The hdWGCNA analysis ultimately identified five core GRPS, namely DDIT4, FKBP4, CHPF, EFNA3, and B3GNT3. In addition, there are significant differences in sensitivity to most drugs between high-risk and low-risk cohorts, with WIKI4 and Lapatinib negatively correlated with risk scores, while Doramapimod and Niraparib positively correlated with risk scores. This study established a GRPS based risk feature for LUAD, demonstrating strong predictive power for prognosis assessment. The drug sensitivity results also provide drug guidance for the clinical application of this feature, all of which provide important clinical utility for the prognosis of LUAD. At the same time, the intercellular communication network was plotted based on the GRPS score, providing insights into the pathogenesis of LUAD and offering new ideas for developing targeted therapies and precision medicine methods. - Source: PubMed
Publication date: 2026/04/13
Tang YalanXiao JundanZhong XiaoweiChen Zhigang - The aim of this study was to explore the prognostic significance of necrotic cell death triggered by sodium overload (NECSO)-related genes in lung adenocarcinoma (LUAD) and construct a prognostic model with high predictive efficiency. The findings will enable a precise stratification of the prognostic risk of patients with LUAD. Analysis of the constructed prognostic model, immune cell infiltration, and tumor mutational burden (TMB) will facilitate the development of individualized precision medical protocols. - Source: PubMed
Publication date: 2026/03/02
Liang LiWang XiaoqiLiu HuihuiHuang TingZhu QuanLu FangguoChen Chunjing - Aberrant glycosylation is implicated in tumor progression. However, the role of β-1,3-N-acetylglucosaminyltransferase 3 (B3GNT3) in non-small cell lung cancer (NSCLC) remains poorly understood. - Source: PubMed
Publication date: 2026/03/16
Lin YingZhang YaoYu BoWang JialeiWu ZhengWang Huijie - Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality globally. Transcobalamin 1 (TCN1) is a driver associated with the progression of various cancers. However, the role of TCN1 in NSCLC remains elusive. The current research aimed to disclose the biological function and regulatory mechanisms of TCN1 in NSCLC. The expression pattern of TCN1 in NSCLC was first identified via qRT-PCR and western blotting. Functional assays including CCK-8, Transwell, Epithelial-mesenchymal transition (EMT), and glycolysis detection were performed to evaluate the effects of TCN1 on the malignant phenotype of NSCLC cells. Then LinkedOmics database and KEGG pathway analysis were employed to explore TCN1-mediated molecular pathways. Finally, the rescue tests were conducted to validated the underlying molecular mechanisms. Here, we observed that TCN1 was apparently overexpressed in NSCLC and predicted poor prognosis. TCN1 knockdown restrained the proliferation, metastasis, EMT, and glycolysis of NSCLC cells. Mechanism studies demonstrated that TCN1 positively regulated B3GNT3 level via activating the EGFR pathway. Knockdown of B3GNT3 also suppressed the malignant progression and glycolysis of NSCLC cells, and its overexpression partially rescued the effects of TCN1 knockdown. In vivo experiments presented that TCN1 knockdown attenuated tumor growth in the xenograft mouse model and downregulated B3GNT3 expression. Collectively, TCN1 overexpression aggravated NSCLC progression by regulating the expression of B3GNT3. The TCN1-B3GNT3 axis served a key part in the growth, migration, invasion, and glycolysis of NSCLC cells, making it a potential therapeutic target for NSCLC treatment. - Source: PubMed
Publication date: 2026/01/20
Zhou HuiCui YayunLi Lailing - Breast cancer is a leading global health concern, with lymph node metastasis (LNM) being a key prognostic factor affecting patient outcomes. Glycosylation-related enzymes such as calcium-activated nucleotidase 1 (CANT1) and Beta-1,3-N-acetylglucosaminyltransferase 3 (B3GNT3) have been implicated in tumour progression, yet their roles in breast cancer, particularly invasive ductal carcinoma (IDC), are not well defined. This study investigates the immunohistochemical expression and correlation of CANT1 and B3GNT3 in IDC and their potential role in predicting LNM and clinical outcomes. - Source: PubMed
Publication date: 2026/01/16
Thabet Dalia MostafaAbu Bakr Al Shaimaa Wagdy Kassem